Le Lézard
Classified in: Health
Subject: ATY

Contact The Gross Law Firm by April 15, 2024 Deadline to Join Class Action Against InMode Ltd.(INMD)


NEW YORK, March 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of InMode Ltd. (NASDAQ: INMD).

Shareholders who purchased shares of INMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/inmode-loss-submission-form/?id=72577&from=4

CLASS PERIOD: June 4, 2021 to October 12, 2023

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) InMode heavily discounts almost every device it sells; (ii) demand for InMode's products was driven by InMode's willingness to discount its products; (iii) InMode violated U.S. Food and Drug Administration ("FDA") regulations by engaging in off-label marketing and promoting products for treatment of indications for which they lack FDA approval; and (iv) InMode violated FDA regulations by failing to timely report injuries caused by its devices.

DEADLINE: April 15, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/inmode-loss-submission-form/?id=72577&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of INMD during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 15, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm


These press releases may also interest you

at 08:40
Babson Diagnostics, a science-first health care technology company, today announced a partnership with Cynergy Wellness, Inc., a privately-owned provider of nationwide physician services for workplace screening and consumer health. Under the terms of...

at 08:37
The Seven Cells team is delighted to re-introduce Tirzepatide, their latest innovation in telehealth pharmacy services. Tirzepatide, featuring the same active ingredient found in the esteemed medications Mounjaro and ZepBound, represents a...

at 08:35
PAVmed Inc.  ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and...

at 08:33
California Vitality, a dynamic new brand offering a range of high-quality supplements, is thrilled to announce its official launch. With a focus on promoting holistic wellness, California Vitality aims to empower individuals to take control of their...

at 08:15
The latest product innovation by NICO Corporation is described as a "game-changing advancement" by neurosurgeons with early experience using the NICO Myriad SPECTRA System ? the ONLY hand-held technology delivering blue excitation light to enhance...

at 08:05
Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVEtm, to develop differentiated small molecule therapeutics, today announced that its...



News published on and distributed by: